Health
Late-Breaking Data at ACC.21 Show XARELTO® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization – PRNewswire
/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO®…
RARITAN, N.J., May 16, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent…
-
General13 hours agoPolice investigating after body found on road in Newborough, Gippsland
-
Noosa News5 hours agoWhy the Brisbane City Hall clock has fallen silent
-
Noosa News17 hours agoNew One Nation branch | Noosa Today
-
Noosa News7 hours agoFederal government to review trade restrictions for Philippine banana imports